| The influence of interferon-alpha and combination interferon-alpha and lamivudine therapy on height and weight in children with chronic hepatitis B infection. | |
| | |
MedLine Citation:
|
PMID: 17642422 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To evaluate the height and weight patterns of children with chronic hepatitis B (CHB) with and without treatment. METHODS: Thirty-four patients with immunoactive CHB randomly assigned to receive interferon-alpha2a (IFN) (5 mIU/m2, 6 months, group I) or IFN (same dose and duration) plus lamivudine (4 mg/kg/day, 24 months) (group II). Fifteen immunotolerant patients (group III) were followed without any treatment. Height (Ht-SDS), weight (Wt-SDS) and growth velocity (GV-SDS) standard deviation scores were monitored for a total of 36 months. RESULTS: Ht-SDS was significantly lower in group II than in group I one year after completion of IFN treatment (p < 0.05). Wt-SDS was significantly higher in group I than the other groups two years after completion of IFN treatment (p < 0.05). In groups I and II, the percentage of children showing abnormal GV-SDS decreased once treatment was completed (p < 0.05). CONCLUSION: CHB does not have deleterious effects on height and weight. Although IFN treatment temporarily compromises weight gain and growth velocity, lamivudine does not have any additional adverse effect. |
| | |
Authors:
|
Zarife Kuloğlu; Aydan Kansu; Fulya Demirçeken; Z Serap Arici; Merih Berberoğlu; Gönül Ocal; Nurten Girgin |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of pediatric endocrinology & metabolism : JPEM Volume: 20 ISSN: 0334-018X ISO Abbreviation: J. Pediatr. Endocrinol. Metab. Publication Date: 2007 May |
Date Detail:
|
Created Date: 2007-07-23 Completed Date: 2007-08-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9508900 Medline TA: J Pediatr Endocrinol Metab Country: England |
Other Details:
|
Languages: eng Pagination: 615-20 Citation Subset: IM |
Affiliation:
|
Division of Gastroenterology, Department of Pediatrics, Ankara University, School of Medicine, Ankara, Turkey. zarifekuloglu@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antiviral Agents
/
administration & dosage,
adverse effects Body Height / drug effects* Body Weight / drug effects* Child Child, Preschool Drug Therapy, Combination Female Growth Disorders / chemically induced* Hepatitis B, Chronic / drug therapy*, virology Humans Interferon-alpha / administration & dosage*, adverse effects* Lamivudine / administration & dosage*, adverse effects* Male |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Interferon-alpha; 134678-17-4/Lamivudine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Weight deficit at birth and Turner's syndrome.
Next Document: Carbohydrate metabolism changes in cystic fibrosis.